BAD HOMBURG, Germany, Nov.25, 2021 / PRNewswire / – On September 10, 2021, Fresenius Kabi was pleased to announce the winner of its innovative JUMPstart research grant and education program. JUMPstart is an initiative that aims to promote research in the field of parenteral nutrition through mentoring, education and the creation of contact networks of doctors and researchers. Funding is awarded to help advance innovative community-led parenteral nutrition research to make a difference for critically ill patients.
This year’s winner is Prof. Stefan Schaller MD de Charité – Universitätsmedizin Berlin, Germany, for his proposal entitled “Improved muscle metabolism by combination of muscle activation and protein substitution”. This cutting-edge study aims to explore the effect of protein replacement before and after early target-directed mobilization in the acute phase of critical illness. The announcement was made at the Congress of the European Society for Clinical Nutrition and Metabolism (ESPEN).
During the virtual award ceremony, Professor Schaller commented: “After working for so long on this research proposal, my research team and I are excited to be able to carry out the study now, and I am very grateful for the generous grant from Fresenius Kabi. I am very optimistic that this trial will have an impact on nutritional therapy in critical care ”.
Professor Schaller participated in the program along with 18 other participants from around the world, including representatives from Africa, Asia, Australia, Europe, New Zealand, North America and South America. After four training sessions, participants presented their research proposals to an independent international scientific committee made up of five leading experts in the field: Prof. Mette Berger, from Switzerland; Prof. Olav Rooyackers, from Sweden; Prof. Tim peace, from Germany; Prof. Robert Martindale, from the United States; and Prof. Ho-Seong Han, from South Korea. The committee was impressed by the high level of quality of all submissions, which made choosing a winner extremely difficult.
Dr Jos Simons, Executive Vice President of Fresenius Kabi, said: “We are absolutely delighted to be able to award this research grant to Professor Schaller. Both the scientific committee and Fresenius Kabi were amazed by his proposal and the positive impact it will have on clinical practice. We are very excited that Professor Schaller is starting this clinical study. “
This is the second JUMPstart research grant to be awarded worth € 250,000. The first 19-participant program was completed in 2019 and awarded the grant to the dietitian Lizl Veldsman, from the Tygerberg Academic Hospital in Cape Town, South Africa.
With the JUMPstart research grant and education program, Fresenius Kabi supports the next generation of clinical experts who will advance nutritional therapy in critically ill patients.
Fresenius Kabi is a global healthcare company specializing in life-saving drugs and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critical and chronic patients. Fresenius Kabi’s product portfolio comprises a wide range of generic intravenous drugs, infusion therapies and clinical nutrition products, as well as the devices for the administration of these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first Fresenius Kabi biosimilar product was launched. In the field of transfusion medicine and cell therapies, Fresenius Kabi offers products for the collection of blood components and extracorporeal therapies.
With its corporate philosophy of “taking care of life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and find the best answers to the challenges they face.
Fresenius Kabi employs around 40,500 people worldwide. In 2020, the company posted sales of around € 7 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.
For more information, visit www.fresenius-kabi.com
This publication contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors; for example, changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, fluctuations in foreign exchange rates, uncertainties in litigation or investigation procedures, and availability of funding. Fresenius Kabi assumes no responsibility for updating the forward-looking statements in this publication.
Board of Directors: Michael Sen (president), Marc Crouton, John Ducker, Dr. Oskar Haszonits, Dr. Christian Hauer, Dr. Michael Schönhofen, Gerrit Steen
President of the Supervisory Board: Stephan Sturm
Registered address: Bad Homburg, Germany
Registro comercial: Bad Homburg District Court – HRB 11654
PINK CARROTS Communications GmbH
Email: [email protected]
Telephone: +49 69 4272614-141
SOURCE Fresenius Kabi